China Forbids Glaxo VP From Leaving In Bribery Probe

China blocked GlaxoSmithKline's (GSK) local head of finance from leaving the country amid a bribery investigation.

Investors appeared to take the report in stride and shares rose in Wednesday afternoon trading after the company disclosed the investigation.

The travel restriction on the British drugmaker's vice president for finance in China, Steve Nechelput, was imposed at the end of June, the company said. Nechelput wasn't arrested and is free to move around the country.

The drugmaker's stock hit a more than five-year intraday high 54 on May 28 before consolidating. Glaxo's revenue has fallen in three of the last four quarters.

Among the largest companies in the Medical-Ethical Drugs group, ranked a healthy 34 on IBD's list of 197 industry groups, Pfizer (PFE) was up 0.4% and Merck (MRK) 0.2%, while Swiss-based Roche Holding (RHHBY) fell 1%.

In the related biotech drugmakers group, Celgene (CELG), which is on the IBD Leaderboard list of highly rated stocks near a buy point, rose 1.3%.

Four senior GSK Chinese executives have been detained by police in connection with the probe, including Vice President and Operations Manager Liang Hong, who has said on Chinese state television that he funneled money through travel agencies by arranging conferences, including some that were never held.

Drug companies are homing in on the fast-growing Chinese market. Market tracker IHS Health expects China to pass Japan as the world's second-biggest drug market behind the U.S. by 2016.

In its statement Wednesday, Glaxo said it's cooperating with Chinese authorities on the investigation.

"GSK has zero tolerance for any behavior of this nature," the company said.

It said it's put an immediate stop to use of travel agencies identified in the investigation and it's conducting its own internal review of transactions related to the agencies.

China blocked GlaxoSmithKline's (GSK) local head of finance from leaving the country amid a bribery investigation.

Investors appeared to take the report in stride and shares rose in Wednesday afternoon trading after the company disclosed the investigation.

The travel restriction on the British drugmaker's vice president for finance in China, Steve Nechelput, was imposed at the end of June, the company said. Nechelput wasn't arrested and is free to move around the country.

The drugmaker's stock hit a more than five-year intraday high 54 on May 28 before consolidating. Glaxo's revenue has fallen in three of the last four quarters.

Among the largest companies in the Medical-Ethical Drugs group, ranked a healthy 34 on IBD's list of 197 industry groups, Pfizer (PFE) was up 0.4% and Merck (MRK) 0.2%, while Swiss-based Roche Holding (RHHBY) fell 1%.

In the related biotech drugmakers group, Celgene (CELG), which is on the IBD Leaderboard list of highly rated stocks near a buy point, rose 1.3%.

Four senior GSK Chinese executives have been detained by police in connection with the probe, including Vice President and Operations Manager Liang Hong, who has said on Chinese state television that he funneled money through travel agencies by arranging conferences, including some that were never held.

Drug companies are homing in on the fast-growing Chinese market. Market tracker IHS Health expects China to pass Japan as the world's second-biggest drug market behind the U.S. by 2016.

In its statement Wednesday, Glaxo said it's cooperating with Chinese authorities on the investigation.

"GSK has zero tolerance for any behavior of this nature," the company said.

It said it's put an immediate stop to use of travel agencies identified in the investigation and it's conducting its own internal review of transactions related to the agencies.

See Also

Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals tracked by Morningstar Inc. over the five years ...

The Big Cap 20 is showing itself to be a good representation of today's market leadership, as technology, health care and consumer stocks dominate the list. A glance of the IBD Smart NYSE + Nasdaq Tables shows chips, medical, apparel, retail and other technology sectors make up most of the top 10 ...

Specialty drugmaker Endo International (NASDAQ:ENDP) beat analysts' Q4 estimates and announced the $1.65 billion sale of its urology-device business Monday, sending the stock to a new high. Endo said earnings rose 21% over the year-earlier quarter to $1.16 a share, beating analysts' consensus by 4 ...

Celgene is a company built on a premise that would make most corporate executives shudder. The premise: find applicable uses for derivatives of thalidomide, a drug banned by the FDA in 1961 after causing tens of thousands of birth defects. But the rock-solid biotech stuck to its ...

02/27/2015 06:51 PM ET

More Business Articles:

U.S. auto sales grew at a slower pace than analysts expected in February as cold weather was more of a deterrent for consumers than lower fuel prices were an incentive. The seasonally adjusted annualized rate of sales also cooled off, slowing to a pace of 16.23 million units from 16.66 million in ...

As AutoZone (NYSE:AZO) reached a new high on view-topping earnings on the stock market today, industry group peer and IBD 50 stock O'Reilly Automotive (NASDAQ:ORLY) is showing strength in tight trading after it broke out on earnings last month. Watch this video for in-depth IBD analysis of the two ...

Macau's gambling revenue tumbled almost 49% as China's anti-corruption campaign continued and high rollers took their money elsewhere in February. But the timing of the Lunar New Year also impacted results, says one analyst. Monthly gross revenue sank 48.6% to 19.5 billion patacas, or $2.4 billion, ...

Dick's Sporting Goods (NYSE:DKS) scored points with investors after the retailer posted fourth-quarter profits and sales that crushed views on Tuesday morning, sending Dick's stock nearly 4% higher in early trading in the stock market today. By early afternoon, shares were trading up just about ...

Select market data is provided by Interactive Data Corp. Real Time Services. Price and Volume data is delayed 20 minutes unless otherwise noted, is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services terms. All times are Eastern United States. *Reflects real-time index prices.